CVAC

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Friday, May 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Retrieved on: 
Friday, May 3, 2024
University, Berea College, Hearing loss, Cardiology, CVAC, Johnson & Johnson, Business development, Research, Business, CureVac, Neurology, Systems biology, Infection, Messenger, MBA, Therapy, Amgen, Pharmaceutical industry

Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas

Key Points: 
  • Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 — CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
  • “Thaminda’s extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across multiple therapeutic areas,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac.
  • He joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.
  • With an educational background in both immunology and business, Mr. Ramanayake began his career as a scientist at Johnson & Johnson and later held a succession of Wall Street business development and consulting roles.

EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Retrieved on: 
Friday, May 3, 2024
University, Cell, Monroe Dunaway Anderson, CVAC, Malignancy, MD, RNA, Vaccine, IND, CureVac, Patient, Collaboration, MD Anderson Cancer Center, Assistant, Messenger, Antigen, Evolution, Drug discovery, Therapy, Whole genome sequencing, Investigational New Drug

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

Key Points: 
  • Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
    MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development, commercialization, or partnering of cancer vaccine candidates
    TÜBINGEN, Germany/HOUSTON, Texas, USA – April 16, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
  • The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research.
  • The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.
  • “We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,” Shukla said.

EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Retrieved on: 
Friday, May 3, 2024
Ageing, Infection, H5N1, Messenger, Human, CureVac, CVAC, Influenza, GSK, Safety, Virus, Vaccine

The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans.

Key Points: 
  • The H5N1 avian influenza virus is considered a potential future pandemic threat, known to sporadically cross species from its original bird host to other animal hosts and humans.
  • The monovalent vaccine candidate is based on CureVac’s proprietary second-generation mRNA backbone and encodes an influenza A H5-antigen.
  • In the initial Phase 1 dose-escalation part of the study, up to five dose levels will be assessed compared to a placebo control.
  • It focuses on applying CureVac’s mRNA-technology to the development of new products for infectious disease targets.

EQS-News: CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Retrieved on: 
Friday, May 3, 2024
EST, CVAC, Webcast, Clothing

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Key Points: 
  • CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
    The issuer is solely responsible for the content of this announcement.
  • CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
    TÜBINGEN, Germany/BOSTON, USA – April 18, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, and provide business updates for the fourth quarter and full-year 2023 on Wednesday, April 24, 2024.
  • The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.
  • Dial-in numbers to participate in the conference call:
    Corresponding presentation slides will be posted shortly before the start of the webcast.

EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Retrieved on: 
Wednesday, April 10, 2024
GSK, Ageing, CureVac, CVAC, Antigen, Messenger, Candidate, Safety, Vaccine

The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.

Key Points: 
  • The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.
  • Targeted optimizations to further improve immune responses against influenza B strains will be tested in an additional Phase 2 study.
  • “The Phase 2 interim data show that CureVac’s highly effective and flexible mRNA technology platform puts us on the right track to advance our joint seasonal influenza vaccine program,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.
  • For older adults, immune responses were compared to a high dose seasonal flu vaccine.

Calyxo Announces FDA Clearance for New, Redesigned CVAC System

Retrieved on: 
Tuesday, March 26, 2024
FDA, General Health, Health, Medical Devices, MGH, Kidney, American Urological Association, Urology, Massachusetts General Hospital, Infection, Incidence, SURE, Patient, CVAC, Kidney stone disease, MD, Trial of the century, Dust, Karger Publishers, Vacuum, Pain, Ureteroscopy, Hospital, Medical imaging

Calyxo, Inc. , a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment.

Key Points: 
  • Calyxo, Inc. , a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment.
  • More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback.
  • Based on learnings from over two years of real-world use, Calyxo reimagined its CVAC System to further enhance the SURE procedure.
  • “CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.

EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Retrieved on: 
Friday, January 5, 2024
Messenger, CVAC, Vaccine, Ageing, Vaccination, Omicron, GSK, COVID-19, Interim, CureVac, Safety

Both vaccine candidates are being developed in collaboration with GSK.

Key Points: 
  • Both vaccine candidates are being developed in collaboration with GSK.
  • Selected data can be reviewed in the presentation associated with this press release.
  • All three of the dose levels tested were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.
  • “These positive Phase 2 data continue to strongly validate the competitiveness of our proprietary mRNA-technology platform and second-generation mRNA backbone in comparison to a licensed mRNA-based vaccine,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Retrieved on: 
Tuesday, December 26, 2023
BioNTech, CVAC, Federal court, Patent, Federal Patent Court (Germany), Messenger, COVID-19, CureVac, Bird, Vaccine, Justice, Sąd rejonowy, COVID-19 vaccine, EP 1, Intellectual property, LLP

CureVac will appeal before the German Federal Court of Justice.

Key Points: 
  • CureVac will appeal before the German Federal Court of Justice.
  • The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights.
  • “We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year.
  • The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®.

EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Retrieved on: 
Tuesday, December 26, 2023
Survival, Research and development, BioNTech, CureVac, Workforce, Operating cost, GSK, Epitope, Webcast, Safety, Business development, RNA, CVAC, Conference, Sąd rejonowy, Astrocytoma, Neoplasm, Pfizer–BioNTech COVID-19 vaccine, Development, Vaccine, Commercial, LNP, Phase II, Acquisition, Immortalised cell line, Animal, GMP, Interim, Palatine Higher Regional Court, Patent, SARS-CoV-2, Tumor microenvironment, Toxicity, Glioblastoma, Antigen, Therapy, Research, Messenger, Mouse, COVID-19, Infection, Clinical trial, District court, Cancer, Patient, CMO, CD8

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – November 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2023 and provided a business update.
  • Positive preliminary data reported in early 2023 in COVID-19 and flu provided strong validation of CureVac’s mRNA technology platform.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first nine months of 2022 were positively impacted by €36.8 million related to the reversal of an outstanding CRO provision.